The Second Xiangya Hospital Of Central South University
发明人:
申请号：
EP18814147.7
公开号：
EP3650030A1
申请日:
2018.05.25
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The present invention is directed to provide application of lncRNAs ENST00000607393 SiRNA in preparation of a preparation for treating glaucoma. The present invention clarifies the correlation between the expression level of ENST00000607393 and the calcification of human primary trabecular meshwork cells. The expression level of ENST00000607393 in human primary trabecular meshwork cells is firstly down-regulated to 46.21% of a control group by siRNA interference. Under the condition of intervening with the cells by a 500 µmol/L hydrogen peroxide solution for 48 hours, it is observed that compared with the control group, the down-regulation of ENST00000607393 expression can significantly decrease the ALP activity in human primary trabecular meshwork cells, and thus significantly decrease the calcification level of human primary trabecular meshwork cells to play a role of treating or preventing glaucoma.
